Lilly Halts Development of Glenmark’s TRVP-1 Receptor Antagonist

MUMBAI - Glenmark Pharmaceuticals suffered a major blow to its drug discovery plans as Eli Lilly, its research partner for the development of pain management compound GRC 6211 suspended further clinical development on the experimental drug